An experimental Covid-19 treatment pill called molnupiravir is being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP. Photo: Handout
An experimental Covid-19 treatment pill called molnupiravir is being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP. Photo: Handout
SCMP Editorial
Opinion

Opinion

Editorial by SCMP Editorial

Pill will not surpass need for vaccination

  • Governments are scrambling to secure supplies of an experimental anti-viral drug that is hoped will keep those most at risk of Covid-19 out of hospital and lower their chances of dying from the disease. But this development is no reason to sideline vaccinating as many people as possible

An experimental Covid-19 treatment pill called molnupiravir is being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP. Photo: Handout
An experimental Covid-19 treatment pill called molnupiravir is being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP. Photo: Handout
READ FULL ARTICLE